PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

 
Press Releases
  Date Title and Summary View
Jul 30, 2015
SOUTH PLAINFIELD, N.J., July 30, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the second quarter ending June 30, 2015. "PTC is progressing on many fronts across the organization.  We are excited to be near the completion of the largest Duchenne muscular dyst...
Jul 16, 2015
SOUTH PLAINFIELD, N.J., July 16, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2015 financial results and provide an update on the company's business and outlook on Thursday, July 30, 2015 at 4:30 p.m. (ET) after the closing of the market....
Jun 23, 2015
Please replace the press release from June 23rd, 10:30 am ET with the following corrected version. The corrected version reads: PTC Therapeutics' CEO Stuart W. Peltz, Ph.D. Finalist For The 2015 NJBiz Innovation Hero Award SOUTH PLAINFIELD, N.J., June 23, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) is proud to annou...
Jun 15, 2015
SOUTH PLAINFIELD, N.J., June 15, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Glenn D. Steele Jr., M.D., Ph.D. to the company's Board of Directors. Dr. Steele served as President and Chief Executive Officer of Geisinger Health from March 2001 until May 2015 and is now Chairman of xG Health Solutions,...
Jun 12, 2015
SOUTH PLAINFIELD, N.J., June 12, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 9, 2015 it approved non-statutory stock options to purchase an aggregate of 55,200 shares of its common stock to 8 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our new hi...
Jun 12, 2015
SOUTH PLAINFIELD, N.J. and SAN RAFAEL, Calif., June 12, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that they will host an Industry Update Symposium on Advances in Duchenne Muscular Dystrophy (DMD) and Biomarkers on Monday, June 22nd from 10 am - 1 pm ET at the Le Parker...
May 21, 2015
SOUTH PLAINFIELD, N.J., May 21, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the Benefit Assessment by Germany's Federal Joint Committee (G-BA) indicated that Translarna™ (ataluren) provided a benefit for ambulatory patients aged five years and older with nonsense mutation Duchenne Muscular Dystrophy (nmDMD...
May 15, 2015
SOUTH PLAINFIELD, N.J., May 15, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on May 15, 2015 it approved non-statutory stock options to purchase an aggregate of 112,150 shares of its common stock to 14 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our new h...
May 11, 2015
SOUTH PLAINFIELD, N.J., May 11, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced it has launched STRIVE (Strategies to Realize Innovation, Vision and Empowerment), an awards program aimed at providing funds to patient advocacy organizations to develop unique and collaborative programs that will make meaningful contribution...
May 4, 2015
SOUTH PLAINFIELD, N.J., May 4, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending March 31, 2015. "We are off to a strong start this year. In our first full quarter since the commercial launch, we have seen strong support for access to Tra...
Page:
1
... NextLast
= add release to Briefcase
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue